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Abstract
The Effects of Bisphosphonates on Bone Remodeling: Analysis of Microdamage Targeting by
BMUs, BMU Velocity and Crack Surface Density
By Daniel Wayne Hale
Studies have indicated that microdamage in the bone matrix both activates and "steers" 
BMUs (Basic Multicellular Units, the groups of osteoclasts and osteoblasts that resorb and form 
bone respectively) toward the damage in order to replace damaged bone with new, mechanically 
sound bone. Also, bisphosphonate drugs have been shown to greatly suppress the remodeling 
process and, with such effects, are commonly used in the treatment of osteoporosis. It was 
hypothesized that BMUs do indeed target microdamage around them and tunnel away from the 
dominant lines of force in bone in order to remove the damage. Additionally it was believed that 
bisphosphonates would have a suppressive force on the BMU's ability to seek out and remove 
microdamage. This study explored a further hypothesis that bisphosphonates would decrease 
BMU velocity and osteonal area while increasing crack surface density in a dose-dependent 
manner. Thirty-six rib bone samples were obtained from the Indiana University School of 
Medicine from a three year canine study in which skeletally mature beagles were administered 
the bisphosphonate Alendronate in doses matching, on a body weight basis, those used to treat 
postmenopausal osteoporosis. Control, clinical dose (Alendronate 0.2 mg/kg body weight), and 
five times clinical dose (Alendronate 1.0 mglkg body weight) treatment groups were created with 
12 dogs in each group. Before harvesting rib bones, the dogs were injected with calcein at two 
different time periods to mark areas of new bone formation. For this study, data for mean crack 
length, resorption space density, osteonal area, and crack surface density were obtained from 
IV 
Matt Allen at the Indiana University School of Medicine. BMU velocity was determined by 
measuring the distance between fluorescent labels in longitudinal sections of bone and dividing 
by the time between injections. Statistical analysis supported the hypothesis that BMUs target 
microdamage and bisphosphonates suppress that ability in a dose dependent manner. Also, 
bisphosphonates have a significant suppressive effect on BMU velocity. Analysis shows that 
there is no difference in osteonal area or crack surface density among the three treatment groups 
(CON, ALNO.2, and ALNI.O) leading to the conclusion that bisphosphonates seemed to have 
little effect on osteonal area or crack surface density over the three year study. 
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1. Introduction and Literature Review
Bone Tissue 
The skeletal system of the human body is a highly adaptable and constantly changing 
structure. Bone density is under continuous optimization to produce the highest strength with the 
lowest amount of weight. There are two main types of bone, called compact (cortical) bone and 
trabecular (cancellus) bone respectively, which comprise a majority of the long bones that make 
up the skeleton (Figure 1). 
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Figure 1. Important features of a typical long bone including compact and trabecular bone (1) 
Compact bone resides as the outer layer of a bone and is characterized by circular structures 
called osteons (Figure 2). 
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Figure 2. Osteons in compact bone (1) 
A blood vessel runs through the central canal of each osteon, called a Haversian canal, and is 
responsible for providing nutrients and removing wastes from the surrounding bone cells [1]. 
Compact bone has a high fracture resistance and toughness due to the geometry of the osteon. 
Osteons are built up as oppositely oriented, concentric, circular matrices called lamellae. This 
geometry provides a high level of fracture resistance since the energy of approaching cracks is 
dissipated around the edge of the circular osteon. As the forces acting on an osteon increases, the 
circular layers begin to pull apart and delaminate before they begin to crack. A large amount of 
the energy contained in a crack is dissipated as an osteon "unravels". This behavior gives cortical 
bone a facture toughness of2.2-6.3 MPa-m ll2, elastic modulus of 17.4 GPa, and a high tensile 
ultimate stress of 133 MPa [1]. Trabecular bone is found near the ends of long bones and is 
characterized by a sponge-like geometry with many interconnected struts (Figure 3). 
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Figure 3. Trabecular bone structure (I) 
Trabecular bone is specialized for absorbing and dissipating the energy of impact on bone. The 
geometry of trabecular bone is optimized to support large loads and spread forces acting on 
bones. Due to their geometry, trabecular bone has an elastic modulus of 272 ± 195 MPa and an 
ultimate stress of2.54 ± 0.62 MPa [1]. Through the center of long bones runs the medullary 
canal. This area is filled with bone marrow which contains undifferentiated stem cells that form 
components of the immune system, red blood cells, and bone cells. 
Bone Cells 
The arbitrators of bone turnover are osteonal bone cells; primarily osteoclasts, 
osteoblasts, osteocytes, and bone lining cells. Osteoclasts are multinucleated cells originating in 
the bone marrow. They arise from the fusion of multiple differentiating bone marrow cells. Their 
main function is to absorb bone through the use of enzymes. Existing bone is absorbed at the 
interface between the cellular membrane and the bone surface (brush border) created by 
numerous infoldings of the osteoclasts' plasma membrane [1] (Figure 4). 
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Figure 4. Multinuclear osteoclast (upper right) resorbing bone (lower left). CZ labels clear zones where the cell is 
sealed to the bone surface; RB labels the ruffled border where enzymes are released to break down bone; B labels 
the calcified bone matrix. (1) 
Enzymes are released at the brush border that de-mineralize the bone matrix and then dissolve 
the bare collagen scaffold. In this way osteoclasts are similar to macrophages in that they absorb 
and consume bone. Osteoblasts are mononucleated cells that originate in the bone marrow. 
Growth factors influence the differentiation of bone marrow progenitor cells into osteoblasts [1]. 
Their main function is to generate osteoid tissue (un-mineralized matrix of Type I collagen) as 
they foHow bone absorbing osteoclasts (Figure 5). 
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Figure 5. Osteoblast forming bone. The dark area at the bottom is mineralized bone. Lighter material is osteoid 
produced by the rough endoplasmic reticulum of the cell. A portion of a process of the cell protrudes into the lighter 
osteoid material. (I) 
Osteoblast activation is contingent on osteoclast activation and their relative activities may be 
linked or unlinked. As more osteoid tissue is produced, osteoblasts become trapped in the 
developing matrix and become osteocytes. Osteocytes are connected to other osteocytes in the 
bone matrix through channels called canaliculi. Cytoplasmic processes of neighboring osteocytes 
form gap junctions through which nutrients and chemical signals can pass [1]. The network of 
communication between osteocytes is called the syncytium. Through this network, osteocytes 
can relay information governing apoptosis, increasing forces, and nutrient deprivation. Bone 
lining cells are present on the periosteal and endosteal surfaces of bone and arise from 
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osteoblasts on the surface of bone. They lie in a layer and regulate the movement of calcium and 
phosphate into and out of bone. Also, bone lining cells communicate with osteocytes and receive 
signals in response to high stress levels in the bone matrix. Upon signaling, the cells release 
honnones that activate complacent osteoclasts and migrate from the bone surface to expose bone 
to active osteoclasts. In this way bone lining cells playa role in the modulation of the remodeling 
process. Bone lining cells are thought to inhibit reabsorption of bone as long as they cover the 
bone surface. The cellular unit involved in bone resorption and fonnation is called the Basic 
Multicellular Unit (BMU) (Figure 6). 
Figure 6. BMU. Two multinuclear osteoclasts are visible on the right; osteoblasts are on bone surfaces on the left. 
(1) 
A BMU is composed of osteoclasts that are responsible for bone absorption followed by 
osteoblasts that deposit the caliginous bone matrix. The osteoclasts fonn a cutting cone at the 
head of a BMU that creates a scalloped geometry in the bone matrix as the BMU tunnels. Behind 
the osteoclasts, osteoblasts fonn new bone in the open resorption space (Figure 7). 
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Figure 7. Osteoclasts (on the right) form the cutting cone of the BMU while osteoblasts (on the left) form new bone 
in the space created by the osteoclasts. BMU is traveling to the right. (1) 
BMUs travel longitudinally through bone at a rate of 19.18 ± 8.25 /lm a day and are responsible 
for creating the osteonal structure of compact bone. Other studies have measured BMU velocities 
at about 40 /lm a day [1]. 
Modeling and Remodeling 
Bone turnover can be classified as two different processes: modeling and remodeling. 
During modeling, bone resorption and bone formation are unconnected and the overall 
morphology and shape of bone is changed. Remodeling links the actions of bone resorption and 
formation so that the morphology is unchanged while maintaining the mechanical integrity of 
bone. In remodeling, bone formation is preceded by bone resorption and the process keeps bone 
in constant state of homeostasis. The cellular unit of remodeling is the BMU 
Bone modeling occurs during childhood growth and allows for the "custornization" of a 
bone's shape with respect to the loading conditions acting on it (I]. As previously stated, 
modeling utilizes the disconnected processes of bone resorption and formation. During childhood 
growth, bones increase in length but also need to be modified to the correct geometry to support 
the loads placed on the skeleton. Bone may be removed or added in various locations to achieve 
optimal bone geometry. One example of modeling occurs in the metaphysis of bones, where 
bone is removed by osteoclasts to reduce bone diameter. In areas such as the proximal tibia, a 
widely flaring metaphysis is required so osteoclasts resorb bone on the periosteal surface of the 
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metaphysis to cut the shaft ofbone direction under the growth plate down to size [I]. Another 
example of modeling is the adjustment of the curvature of bones during growth. Specific bones 
require a certain degree of curvature which is achieved by bone removal and formation on 
different sides of bone such that the cross-section "drifts" sideways relative to the ends of the 
bone [1]. The modeling process drastically decreases once skeletal maturity is reached while 
remodeling continues throughout life and becomes the main process through which bone is 
altered. 
Remodeling can be initiated by increased forces and loads acting on bones. One theory of 
remodeling is that bone lining cells, located on the surface of bone, sense stress and strain during 
bone loading and communicate the increase in forces to osteocytes. Osteocytes in the location of 
increasing forces recruit osteoc1asts to begin bone resorption at a specific location. Osteoclasts 
then begin to absorb bone following the major lines of force (stress and strain) followed by 
increased bone formation by osteoblasts. The increased forces on bone guide the osteoclasts by 
activating osteocytes present in the bone matrix which then signal to osteoclasts to begin bone 
resorption. In this way, bone is built up along the principle stress directions altering the bone's 
morphology. 
Remodeling is also believed to be initiated by the activity of osteocytes [1, 2, 4]. In this 
case, remodeling initiation relies on fractures and crack propagation in the bone matrix. 
Osteocytes are either disturbed by propagating cracks or sense the changes in stress distribution 
around them [1, 4, 5]. When a crack is formed, osteocytes in the area surrounding the crack 
undergo apoptosis and release a multitude of chemical signals as they die. A network of 
apoptotic osteocytes forms around the damaged bone and this network attracts active BMUs. The 
recruited osteoclasts begin to absorb bone in the area containing the cracks and fractures, 
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ultimately removing a majority of those structures from the bone matrix. Following the 
resorption performed by osteoclasts, osteoblasts deposit bone in the newly created cavity. As 
osteoblasts continue to generate osteoid tissue they become trapped in the bone matrix and 
become osteocytes. In this way, old, weak bone is replaced with new, mechanically sound bone 
complete with a syncytium of interconnected osteocytes. 
Another activator of the remodeling process is when bone is in a state of disuse. In this 
case, bone experiences a low mechanical stress environment and BMU initiation occurs to 
remove unneeded bone. The skeletal system, like the rest of the body, attempts to operate at the 
highest efficiency possible and will remove metabolically demanding yet mechanically 
unnecessary bone. 
The process of bone remodeling can be divided into six stages. The first stage is called 
the activation stage and it involves the recruitment of osteoclasts from precursor cells. Progenitor 
cells in bone are triggered to become osteoclasts and gather at a specific area to form the 
resorption cone or cutting cone of the BMU. The next stage ofremodeling is called the 
resorption stage. Newly created osteoclasts begin to resorb bone by traveling longitudinally at a 
rate of 19.18 ± 8.25 /lm a day. Other studies have measured BMU velocities at approximately 40 
jJ.m a day [1]. The area of resorption is an ellipsoidal shape with an approximate diameter of 200 
!lm. This diameter can vary between different BMUs. The third stage is called the reversal stage. 
In this stage the transition from osteoclastic bone resorption to osteoblastic bone formation takes 
place. The length of this stage is dependent on the lag time between osteoclast activation and 
osteoblast activation. Typically, the reversal and resorption stages together take about 30 days in 
humans. In a completed secondary osteon the cement line is called the reversal line because it 
denotes where bone formation began to take place in the BMU. The cement line is the boundary 
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around an osteon that separates the newly formed bone of the osteon and the surrounding, older 
bone. The fourth stage of bone remodeling is called the/ormation stage. In this stage, osteoblasts 
around the outer edge of the tunnel formed by osteoclasts begin to create the collagenous 
framework that bone is built upon. Osteoblasts build concentric lamellae at a rate of about 1-2 
flm per day [1]. As the tunnel is filled, bone formation slows and a canal is left in the center of 
the tunnel. This central area, called a Haversian canal, is approximately 40-50 11m in diameter 
and contains an arterial blood vessel. The Haversian canal is necessary because osteoblasts and 
osteoclasts are living cells and need nutrients and a waste disposal system. Also, the blood vessel 
brings phosphate and calcium ions where they are needed in the bone matrix and provides 
nourishment for osteocytes. The next phase is called the mineralization stage and follows the 
formation of bone. Up to this point in the remodeling process, organic, unmineralized osteoid 
tissue is laid down. Within the first few days after the osteoid tissue is formed approximately 
60% of the matrix is mineralized with hydroxyapetite [I]. This stage of mineralization happens 
quickly and is called primary mineralization. Secondary mineralization occurs for the next six 
months and mineralizes the remaining osteonal tissue. Because of the drawn out mineralization 
process, osteons comprised of new bone display different mechanical properties than osteons 
made up of older bone. The last phase of the remodeling process is called the quiescence stage. 
Once the bone resorption and formation processes are fmished, the BMU "disbands" and 
osteoclasts and osteoblasts separate. Approximately 10-20% of the osteoblasts involved in the 
BMU transitioned into osteocytes while some become bone lining cells in the Haversian canal 
and others disappear entirely [6]. Osteoclasts leave the completed osteon and may join another 
BMU. This stage represents the normal activity of an osteon as it functions as a component of the 
bone matrix. 
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Osteoporosis 
The process of bone replacement is fundamental in many life functions. Fracture healing 
is a major occurrence that initiates both bone modeling and remodeling. At the crux of 
osteoporosis lies a malfunctioning case of bone remodeling. Osteoporosis commonly affects 
postmenopausal women over the age of 50 [7]. The disease is characterized by the increasing 
porosity of bone and a decrease in bone's fracture toughness. As bone is remodeled, less bone is 
deposited after the resorption phase [7]. Osteoblasts exhibit decreased functionality while 
osteoclasts continue to function normally. This uneven activity causes the amount of bone 
present to continually decrease. Decreasing bone integrity is also seen in older individuals 
without osteoporosis. As people age, the number of active BMUs decreases and damage begins 
to accumulate [7]. Fracture risk increases due to decreases in the elastic modulus and toughness 
of bone and the increase of microdamage [I, 7]. Older individuals experience increasing levels of 
bone degeneration and daily activities are impacted. 
Current treatment for osteoporosis includes supplementing the diet with vitamin D and 
calcium [7, 8]. Increasing specific vitamins and minerals in the diet helps to decrease bone loss 
by providing a wealth of available building blocks for bone. Another treatment method involves 
exercise utilizing resistance training. Exercise with weights increases the loading on bones and 
stimulates the modeling and remodeling processes to increase bone density. Care must be taken 
by individuals to avoid injury during weight training. A further method of treating osteoporosis 
involves the use of nitrogen-containing bisphosphonate dmgs [8]. 
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Bisphosphonates 
The bisphosphonate class of drugs penetrates the bone matrix and contains chemical 
functional groups that inactivate, disrupt, and kill osteoclasts. Decreasing the action of 
osteoclasts also reduces the processes of bone resorption and bone fonnation. Initially after 
treatment with bisphosphonates, an overall increase in bone density is witnessed as the 
osteoblasts that were previously functioning continue to deposit bone [8]. The tradeoff to 
bisphosphonate use is that microdamage is allowed to accumulate in the bone structure due to the 
reduction of the remodeling process. Recall that remodeling replaces old, damaged bone with 
new, mechanically sound bone. As microdamage accumulates, the risk for fracture may increase 
as well. Alendronate, a common nitrogen-containing bisphosphonate, is given as osteoporosis 
medication under the commercial name Fosamax. 
Nitrogen-containing bisphosphonates have a strong affmity for bone and not for other 
tissues due to their chemical makeup. Bisphosphonates have a characteristic structure seen in 
Figure 8. 
H 
o 0 o 
II I
HO-P-C IIP-OH 
I I 
o R I a 
H H 
Figure 8. Characteristic structure of bisphosphonates. All have a hydroxyl group on the carbon atom and vary only 
at the R group, which always contains a nitrogen atom. (8) 
Bisphosphonates have a similar chemical structure to pyrophosphate which accounts for their 
attraction to calcium ions. The hydroxyl group on the central carbon atom provides a high 
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affinity for calcium circulating in the blood and at the bone surface. Also, the phosphorus­
carbon-phosphorus backbone is highly resistant to biological enzymes that usually degrade 
foreign chemicals [8]. Bisphosphonates are metabolically inactive which allows them to circulate 
the blood stream and exit the body as the original molecule. Variation between bisphosphonates 
occurs at the R group attached to the carbon atom which always contains a nitrogen atom in 
either an alkyl or heterocydic structure [8]. 
Nitrogen-containing bisphosphonates work by interfering with the enzymes utilized by 
osteoclasts during differentiation and bone absorption. Specifically, bisphosphonates inhibit 
famesyl diphosphate synthesis (FPP synthase) [8]. FFP synthases is a crucial part of the 
metabolic pathway that activates small GTPases such as Rab, Rac, Ras, and Rho. These GTPases 
are signaling proteins that when activated regulate important processes and structural properties 
for osteoclast function, including morphology, cytoskeletal arrangement, vesicular trafficking, 
and membrane ruffling [8]. Vesicular trafficking and membrane ruffling are two main osteoclast 
functions that are essential to bone resorption. The ruffled border produced by osteoclasts at the 
bone surface is the site of demineralization and disintegration of the collagen matrix. A 
disruption in osteoclasts' vesicular movement means that the enzymes required for bone 
degradation will not be concentrated at the bone surface and thus will be ineffective. Also, the 
formation of an inadequate ruffled border will inhibit the ability of osteoclasts to resorb bone and 
may dislodge them from the bone surface [8]. The concentration ofbisphosphonate medication 
given also plays a role in the degree of osteoclast activity suppression. Low concentrations 
inhibit the functional osteoclastic activities that involve the cytoskeleton such as vesicular 
trafficking and membrane ruffling [8]. Higher concentrations inhibit osteoclast differentiation 
and at concentrations nearing 100 ~M osteoclast apoptosis is induced [8]. The majority of BMU 
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suppression occurs during the first few months ofbisphosphonate treatment. In a study by 
Kimmel [8], osteoclast function was seen to decrease by 70-80% during the first months of 
treatment and then remain at that level for the entirety of the treatment. Once bisphosphonate 
treatment is stopped, the bone resorption rate increases back to pre-treatment levels. 
The pharmacokinetics of nitrogen-containing bisphosphonates focuses on the drug's 
interaction with body systems. Upon oral administration of the drug, bisphosphonates begin to 
circulate in the bloodstream within a few hours. The drug is then partitioned, approximately 
equally, to the kidneys and skeletal system [8].The hydroxyl group contained on the 
bisphosphonate has equal affinity for calcium ions circulating the blood and found on the bone 
surface. Bisphosphonates reaching the kidneys are eliminated from the body un-metabolized 
through the urine whereas the remainder of the drug is deposited to a certain extent on the 
skeleton. 
Different skeletal areas show different affinities for nitrogen-containing bisphosphonates 
depending on the bone-remodeling activity occurring at the bone surface. The three bone regions 
to be discussed are resting, resorbing, and forming which are associated with the cellular activity 
of bone lining cells, osteoclasts, and osteoblasts respectively. At the resting surfaces, bone is 
covered with bone lining cells and thus has a relatively low affinity and retention rate for 
bisphosphonates [8]. Since the nitrogen-containing bisphosphonates are bound loosely there is a 
chemical gradient that favors their re-uptake into the vascular system within hours to days [8]. A 
large portion of bisphosphonates are processed through the resting surfaces due to the large area 
of bone classified as resting. The resorbing surfaces make up a smaller p0l1ion of the total bone 
surface area but process a large amount ofbisphosphonates because calcium is being released 
from the bone surface into the bone fluids by the activity of osteoclasts. Osteoclasts liberate 
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calcium ions as they dissolve the bone matrix and produce a high local concentration of calcium 
that is available for chelating by bisphosphonates. As more bisphosphonates are attracted to the 
areas of bone resorption, the concentration ofbisphosphonates at these surfaces increases to 
levels sufficient to deactivate osteoclast functions [8]. Once FFP synthase is inhibited, the 
osteoclasts cease functioning. Ifbisphosphonate treatment is halted the concentration of 
bisphosphonates at the resorbing surfaces will be removed within days to weeks ultimately 
reaching full removal to the blood and then the kidneys [8]. Forming surfaces have a high 
affinity for bisphosphonates too due to the high levels of calcium being affixed to osteoid tissue 
during mineralization. All the bisphosphonate at forming surfaces chelates with calcium ions and 
is then buried in the bone matrix [8]. The bisphosphonates will remain in the bone matrix until 
they are uncovered by resorbing osteoclasts and released into the bone fluid which circulates 
back into the bloodstream. Nitrogen-containing bisphosphonates buried in the bone matrix are 
considered biologically inert and have no interaction with any bone cells [8]. When 
bisphosphonates are released by resorbing BMUs they return to the bloodstream and are equally 
partitioned to the kidneys and skeletal system. In this way, bisphosphonates released from the 
bone matrix are able to affect osteoclast function, albeit at lower concentrations than the previous 
dose. Bisphosphonates uncovered during the remodeling process may also affect osteoclast 
function if their local concentration around the osteoclasts is high enough to disrupt FPP 
synthase [8]. 
Even though bisphosphonates specifically target bone tissue and are metabolically 
inactive, there are some side effects associated with their use. Acute inflammation of the 
esophagus and stomach lining is the most prevalent, yet easy to prevent side effect seen with 
bisphosphonate use. Standing or sitting for 30-60 minutes after orally taking the medication is 
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enough to avoid stomach and esophageal ilTitation. Another side effect is hypocalcemia or 
decreased blood calcium levels. This disease arises due to bisphosphonates' high affinity for 
calcium ions. Bisphosphonates circulating in the blood chelate calcium and render it unavailable 
for other functional uses. In some cases ofbisphosphonate use renal impairment occurs due to 
the drugs passage through the kidneys as it is excreted. 
Microdamage Targeting by BMUs 
As previously mentioned, BMUs are initiated by cracks and damage within bone (Figure 
9). 
Figure 9. Microcracks in compact bone. Arrows point to cracks formed between osteoos. (1) 
This damage is caused by normal, everyday activities including walking and lifting objects. One 
theory is that BMUs reabsorb and deposit bone along the lines of force within bone. Another 
theory involving BMU movement during remodeling is that reabsorbing osteoclasts target 
microdamage within bone and shift their movement toward damaged areas [2]. Once the 
damaged bone has been reabsorbed, the BMU tracks back to the nearest dominant line of force in 
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the bone. In this way, bone is strengthened as cells deposit bone along the prominent lines of 
force and repair cracks and damage within bone. 
Studies proposed that osteonal BMUs tunnel in alignment with the local principal stress 
directions [9]. The reasons for this are as follows. Osteocytes need a stress-driven fluid flow 
across their processes to survive and remain active [9]. In the absence of a sufficient stress field 
osteocytes become apoptotic and release a variety of signaling hormones to surrounding 
osteocytes and bone lining cells. These messenger chemicals are a combination of "come eat 
me" and "death announcement" signals that attract nearby osteoclasts and communicate with 
nearby osteocytes [2]. When BMUs are aligned with the principle stress directions, a region of 
very low stress is created slightly ahead of the BMU. This low stress region causes apoptosis of 
nearby osteocytes which then release the signaling chemicals to osteoclasts. The BMUs 
osteoclasts follow the changes in load direction as the apoptotic signal shifts. In this way the 
BMU stays aligned with the dominant stress directions in the bone. 
Focusing on BMU activation and steering by microcracks, remodeling activities and 
BMU movement will be discussed. It can be assumed that a resorbing BMU will remove at least 
a portion of the crack that initiated it and potentially, portions of other cracks encountered during 
its movement. Even though only a portion of the crack will be removed, this is extremely 
beneficial in reducing the probability of crack extension because the stress required to propagate 
a crack is inversely proportional to the square root of its length [10]. With this assumption in 
place, the value of microcrack "targeting" in reducing fracture risk is apparent. In a study 
performed by Martin, mean microcrack lengths were plotted as a function of resorption space 
density for a group of male and female human femur specimens to calculate the average cross­
sectional area of a BMU [2]. The value calculated for average cross-sectional area of a BMU was 
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1.66x106 flm2 which correlates to an osteonal diameter of 1400 flm (assuming circular osteons) 
[2]. This value is much larger than osteonal diameters found for human femurs by Moyle and 
Bowden [11] which ranged from 150 to 220 flm. An osteonal diameter of 220 flm corresponds to 
an osteonal area ofO.038xl06 flm2 which is only 2.3% of 1.66xl06 flm2. From these calculations 
it can be observed that BMUs are resorbing bone as if they were much larger than they really are. 
Martin's calculations represented an "effective BMU area" and not the actual BMU area [2]. The 
effective area surrounding the trajectory of a BMU provides a region through which the BMU 
can steer in order to remove microdamage. 
Martin [2] discussed the possibility of a larger effective BMU area by focusing on two 
questions: 
I) How do a BMU's osteoclasts sense microdamage through several hundred)..tm 
of intervening bone matrix and direct their resorption toward it? 
2) When signals for steering toward microdamage and steering in alignment with 
principle stress direction compete, how are they integrated or resolved? 
In response to the first question, focus is placed on the signaling molecules Bax and Bcl-2. Bax 
is a molecule commonly expressed in cells undergoing apoptosis [2]. Bcl-2 is a molecule with a 
chemical structure similar to Bax but with the function of aiding in cell survival. Due to their 
similar chemical structure, Bax and Bcl-2 can form homodimers and heterodimers that play 
important roles in regulating osteocyte apoptosis. Homodimers of the Bax molecule result in 
mitochondrial structures that produce apoptosis and heterodimers of Bax and Bcl-2 protect 
against apoptosis [2]. The following figure, generated by Verborgt et a1. [4], shows the 
distribution of cells exhibiting Bax and Bcl-2 with respect to their relation to microcracks (Figure 
10). 
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Figure 10. Schematic diagram approximating osteocyte expression ofBax and 8cl-2 as a function of distance from a 
microcrack. The gray area represents the hypothetical ~700 /lm radius of the effective osteonal area calculated by 
Maltin [2]. Bax diminishes to zero over a distance of about 4 nun. Bcl-2 approximately doubles over a distance of 
1.5 nun away from the crack and then decreases to zero at 4 nun. The solid line suggests a net expression ofBax and 
BcI-2, i.e., the difference between the Bax and Bcl-2 signals. (4) 
By examining the graph it can be seen that cells exhibiting Bax, apoptotic cells, reside closest to 
the microcrack with the density of such cells decreasing linearly toward zero over a distance of 
about four mm. Conversely, the density of cells exhibiting Bcl-2 starts low nearer to the 
microcrack and then doubles at a distance about 1.5 mm away from the crack. Then the 
concentration of Bcl-2 drops linearly to zero at about 4 mm away from the crack. It was 
concluded by Verborgt [4] that "targeting and guidance of bone resorption to sites of 
microdamage may be caITied out not only by signals from apoptotic cells near damage sites, but 
also by signals from surrounding cells expressing apoptosis-inhibiting gene products". These 
observations show that healthy cells residing significant distances away from microcracks are 
protected from apoptosis, and thus resorption, while cells nearer to microcracks are influenced to 
undergo apoptosis and thus amplify the signal for resorption. The solid line in the figure shows 
the relative values of Bax and Bcl-2 illustrating the protective and shielding nature of Bcl-2 as 
one moves further from a microcrack. The shaded region in the figure depicts the 700 /.lm 
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distance from a microcrack that can be accessed by a steered BMU. In this region the solid line 
increases in magnitude as distance to the microcrack decreases, showing that Bax is the 
dominant molecule influencing apoptosis of surrounding cells and signaling of BMUs. 
The second question looks at the resolution between conflicting steering mechanisms of 
microcracks and the dominant lines of force in bone. As previously discussed, an area of low 
force develops in front of a tunneling BMU resulting in apoptosis of those osteocytes residing in 
that area. The apoptosis of these osteocytes attracts osteoclasts which home in on the region of 
apoptotic cells. When this apoptotic area in front of a BMU merges with the apoptotic region 
surrounding a rnicrocrack, the osteoclasts are attracted to the center of the denser region of 
apoptotic osteocytes. The BMU is drawn closer to the center of this area where lies the 
microcrack. Thus, the target of the BMU shifts from the dominant line of force to the 
microcrack, its associated array of apoptotic osteocytes, and the chemical gradient produced by 
signaling molecules [2]. Once the BMU passes through the microcrack it will track back to the 
local stress field as its osteoclasts are attracted to the dominant loading patterns in the bone. 
Martin concluded that the direction of BMU advancement is dependent on alignment 
with the principle stress directions and targeting the removal of damage [2]. The degree to which 
the trajectory of a BMU is altered to seek out and remodel microdamage is dependent on the 
ability of signals to attract a BMU's osteoclasts. Osteocytes and their messenger chemicals 
released during apoptosis are integral to this observation. 
Hypothesis 
The goal of this thesis is to investigate the relationship between bisphosphonate 
medications and the remodeling process to see if the remodeling-suppressing drugs have an 
effect on BMU steering and movement ofBMUs. Measurements will be made on longitudinal 
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sections of canine rib bones to determine the distance between fluorescently tagged bands of new 
bone growth. These distances along with the known time between administrations of the 
fluorescent labeling will yield the velocity of the BMUs as they tunnel through bone. Data from 
Matt Allen's research group at the Indiana University School of Medicine along with 
measurements taken on the longitudinal bone sections will be utilized to determine the effects of 
bisphosphonates on BMU steering and BMU movement. Three hypotheses were formed from 
the general objectives: 
1. Data will lend support to Martin's theory [2] that BMUs are steered towards 
microcracks by demonstrating that tunneling BMUs have an effective resorption 
area that is much greater than the actual area of an osteon. 
2. Bisphosphonates will have the effect of decreasing the calculated effective 
resorption area of tunneling BMUs, and thus decrease their ability to steer, and 
the decrease in the effective resorption area is correlated to dose concentration. 
3. Bisphosphonates will have the effect of reducing BMU tunneling velocity and 
measured osteonal resorption area (in a dose dependent manner) thus effecting a 
new equilibrium crack surface density, under the assumption of steady state 
damage formation and removal. 
21 
2. Materials and Methods
Experimental Design 
Bone samples came from a 3-year study performed by the Indiana University School of 
Medicine involving the daily administration of bisphosphonate drugs to skeletally mature 
beagles [12, 13, 14]. All experimental procedures were approved by the Indiana University 
School of Medicine Animal Care and Use Committee. Female beagles (1-2 years old, n = 36) 
were confirmed to be skeletally mature (closed proximal tibia and lumbar vertebral growth plates 
on X-ray) prior to the start of the study [12]. Treatment involved daily, oral doses of vehicle 
(VEH, ImL/kg saline) or Alendronate (ALN, 0.2 or 1.0 mglkg; Merck, Rahway, NJ) 
administered by syringe. The lower dosage (0.2 mg/kg) corresponds to clinical levels of 
bisphosphonates used to treat postmenopausal osteoporosis while the larger dosage (1.0 mg/kg) 
corresponds to bisphosphonate levels used to treat Paget's disease [13]. Both dose sizes were 
prepared by mixing Alendronate in saline to produce a 0.05% (lower dose) and a 0.2% solution 
(higher dose). In each preparation, a correction was used to account for the 16.4% moisture 
content of Alendronate [12]. Dosing was performed each morning after an overnight fast and at 
least two hours prior to feeding. 
To label newly formed bone, calcein (5 mg/kg as a 3% solution) was intravenously 
administered on a 2-12-2-5 labeling schedule preceding necropsy. The animals were killed by 
intravenous injection of sodium pentobarbital (0.22 mg/kg Beuthanasia-D Special; Schering­
Plough, Union, NJ[AUl]) [12]. Immediately after death, the midpoint of the ninth rib was 
removed and saved in 70% ethanol for evaluation of microdamage. Also, an adjacent section of 
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the ninth rib was saved in 10% neutral buffered formalin for dynamic histomorphometric 
measurements. 
Microdamage Analysis 
In order to evaluate specimens for microdamage, bone samples were stained en bloc with 
1% basic fuschin and then embedded undecalcified in methyl methacrylate [12]. Two bulk 
stained samples per animal were used to assess microdamage using a semiautomatic analysis 
system (Bioquant OSTEO 7.20.10; Bioquant Image Analysis, Nashville, TN) attached to a 
microscope equipped with an ultraviolet light source (Nikon Optihot 2; Nikon, Tokyo, Japan). 
The possibility of finding no microdamage in any given specimen was reduced by analyzing two 
specimens per animal. Ultraviolet fluorescence was used to measure crack length (Cr.Le), crack 
number (Cr.N), calculations of crack density (Cr.Dn, Cr.N/bone area), and crack surface density 
(Cr.S.Dn, [Cr.N * Cr.Le]/bone area) in the cortex of the rib [18]. All variables were measured 
and calculated in accordance with American Society for Bone and Mineral Research­
recommended standards [15]. Analysis was performed by Matt Allen's group at Indiana 
University and results were obtained for subsequent calculations. 
Sample Preparation 
Bone samples were received embedded undecalcified in methyl methacrylate and stained 
en bloc with 1% basic fuschin. Longitudinal sections were cut from each sample using a high 
precision bone saw (Isomet 1000; Buehler Ltd., Lake Bluff, IL). After cutting, the sections were 
sanded to a thickness of 100 micrometers using a sequence of 400 and 600-grit sandpaper and 
then mounted on microscope slides (Eukitt Mounting Medium; Electron Microscopy Sciences, 
Hatfield, PA). 
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BMU Velocity Measurements 
The velocity of resorbing BMUs, Y.BMU, was calculated by measuring the distance 
between fluorescent calcein labels and dividing that distance by the time between subsequent 
injections of calcein (labeling schedule). Slides were viewed using a fluorescent microscope 
(Olympus BX41; Olympus, Center Valley, PA) and ultraviolet filter (31001 FITC; Chroma, 
Rockingham, VT). The excitation and emission wavelengths of calcein are 495 and 520 
nanometers respectively [16]. Calcein labels of new bone formation appear as parallel bright, 
yellow lines under ultraviolet light. Pictures oflabeled BMUs were taken using imaging software 
(QCapture Pro; QImaging, Surrey, BC, Canada) and imported into image processing and 
analysis software (lmageJ; http://rsb.info.nih.govlijl). A ronchi ruling was used to calibrate the 
length measurements taken using ImageJ. Measurements were made using the method of 
Jaworski and Lok [17] on bone specimens from dogs receiving treatment for three years (Figures 
11 and 12). 
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Figure II. Double labeled BMUs under fluorescent microscope. In BMUs Band D the first and second labels are 
marked as I and II respectively. (17) 
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Figure 12. Schematic representation of a longitudinally sectioned BMU. The distance Q represents the distance the 
BMU traveled between tetracycline labeling injections. (17) 
Jaworski and Lok viewed BMUs under fluorescent microscopy and calculated the distance 
between the end of the first fluorescent label and the end of the second fluorescent label (distance 
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Q in Figure 12). This method was repeated for the current study as can been seen in Figures 13 
and 14. Figures 15 and 16 show two more examples of double-labeled BMUs that were 
measured in this study. 
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Figure 13. Double-labeled, longitudinally sectioned BMU. The BMU was traveling to the left. Labeling injections 
were given 12 days apart, where I represents the fIrst label and II represents the second label. 
Figure 14. BMU in Figure 12 with arrows representing the distances measured to determine BMU velocity. 
Figure 15. Double-labeled longitudinally sectioned BMU with arrows representing the distance measured between 
labels for BMU velocity calculation. 
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Figure 16. Double-labeled longitudinally sectioned BMU with alTows representing the distance measured between 
labels for BMU velocity calculation. 
The three treatment categories were control, low dose bisphosphonate (Alendronate 0.2 mg/kg 
body weight), and high dose bisphosphonate (Alendronate 1.0 mg/kg body weight). At least 
three double-labeled BMUs were located and measured for each longitudinally sectioned 
specimen and the measurements were averaged to yield the average distance for each specimen. 
The average distances for each specimen were divided by 12 (the number of days between 
labeling injections) to determine BMU velocity. The average velocities for each of the 12 
specimens in each treatment group were averaged to determine the overall average velocity for 
each treatment group. 
Histomorphometric Analysis 
Measurements of mean crack length, Cr.Le, and mean BMU resorption cavity density, 
Rs.Ar, for the rib sections were made by Allen et a1. and provided for further analysis. Using a 
model created by Martin [2] to describe BMUs traveling through bone containing microcracks, 
the cross-sectional area of a BMU can be calculated. According to Martin, in a section of bone 
with area AT containing a crack with length Lo, a BMU, with area ABMU, tunneling at random 
through this section of bone will remove a fraction of the crack's length, ~L. The portion of the 
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crack removed by the BMU can also be defined as i1L/Lo= ABMU/AT and the total length of the 
crack is then expressed by the following equation: 
L = Lo - i1L = Lo(1 - i1L/ Lo) = Lo(1- ABMU/AT) [2] (1) 
If multiple BMUs, NR, all with the same area, ABMU, tunnel independently through the section of 
bone at random locations so that none overlap, then the crack length absorbed by the BMUs 
would be NR times as great and the above equation can be re-written: 
L = Lo{ 1 - (NR ABMu)1AT} or L = Lo - ABMuLo(NR IAT) [2] (3) 
Changing to standard histomorphometric notation and noting that NR IAT is equal to the 
resorption spaces per unit area, Rs.Ar, the above equation can be written in the following fonn: 
Cr.Le = iCr.Le - (On.Ar x iCr.Le)Rs.Ar (4) 
Where Cr.Le is the mean crack length, iCr.Le is the mean initial crack length, and ABMu = 
On.Ar, the cross-sectional area of individual osteons [2]. Taking values from multiple bone 
specimens and graphing mean crack length (Cr.Le) with respect to mean resorption space density 
(Rs.Ar) should yield a linear relationship for bone specimens where the slope divided by the 
intercept is equal to the mean osteonal area, On.Ar, of a resorbing BMU. On.Ar represents the 
"effective" osteonal area and may differ from actual calculated osteonal areas if the BMUs travel 
toward and resorb microdamage that they wouldn't nonnally pass through. It is assumed that a 
nonnally tunneling BMU will follow the predominant lines of force in a bone specimen and will 
resorb whichever microcracks the BMU happens to encounter along that path. IfBMUs target 
microdamage then they will veer off of their nonnal path to pursue microdamage lying within a 
certain distance away from the guiding line of force before returning back to their original 
heading. As the BMU constantly weaves through the bone matrix resorbing microdamage and 
following the principal loading directions, its calculated effective osteonal resorption area will 
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appear larger than its measured osteonal area. Three graphs were created in order to calculate 
effective On.Ar for the three year study data consisting of a control bone treatment group, low 
dose (0.2 mglkg) of Alendronate treatment group, and high dose (1.0 mglkg) of Alendronate 
treatment group. Mean crack length and mean resorption space density data needed to perform 
these calculations were provided by Allen et al. and can be seen in Table 1. 
Analyzing Effect ofBisphosphonates 
The effects ofbisphosphonates on microdamage targeting by BMUs were analyzed by 
statistically comparing their calculated effective osteonal resorption areas. As discussed above, 
the effective osteonal resorption areas were calculated for a control group, low dose 
bisphosphonate group (Alendronate 0.2 mg/kg body weight), and a high dose bisphosphonate 
group (Alendronate 1.0 mg/kg body weight). Significance between the groups was calculated to 
determine if there is a relationship between bisphosphonate dose size and the size of the effective 
osteonal resorption area. It is hypothesized that an increase in bisphosphonate dose corresponds 
to a decrease in the effective osteonal resorption area because as bisphosphonates suppress the 
action ofBMUs the ability of BMUs to steer towards microdamage will also be suppressed. 
The effects of bisphosphonates were also explored in an analysis of BMU tunneling 
velocity, osteonal area, and total crack length per unit area of bone cross-section. Assuming that 
BMUs do not target microcracks, they will remove whatever damage they encounter and their 
damage removal rate can be found by the following equation: 
[d(Cr.S.Dn)/dt]removal = V.BMU x On.Ar x Cr.S.Dn (5) 
Where Cr. S.Dn is the total crack length per unit area of a bone cross-section (crack surface 
density) and Y.BMU is the velocity of a tunneling BMU. This equation predicts that the crack 
removal rate is directly proportional to V.BMU, On.Ar, and Cr.S.Dn and will increase or 
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decrease with corresponding changes in the aforementioned variables. As the tunneling velocity 
of a BMU increases, it logically follows that more microdamage will be encountered and 
removed by the BMU. Introduction ofbisphosphonates is assumed to suppress the BMU 
activation rate and subsequently decrease damage removal causing a decrease in tmmeling 
velocity of BMUs and mean osteonal area. When damage formation and damage removal reach 
equilibrium in bone, equation 5 implies that damage formation is equal to V.BMU x On.Ar x 
Cr.S.Dn. This means that when Y.BMU and On.Ar decrease due to the presence of 
bisphosphonates, Cr.S.Dn may increase until a new equilibrium is reached. Increased Cr.S.Dn 
(Cr.S.DnE, where the E stands for the new equilibrium value) may be expressed as: 
E _ [d(Cr.S.Dn)/ dt]/ormar;on
Cr.S.Dn - T T 
V.BMU x On.Ar 
Where V.BMUT and On.ArT are the decreased BMU velocity and mean osteonal area 
respectively, caused by the administration of bisphosphonates. Y.BMU data was measured 
following the methods described by Jaworski and Lok [17]. Cross-sections of bone specimens 
were used to calculate mean On.Ar and Cr.S.Dn. Osteonal area and microcrack length and 
number data were provided by Allen et al. 
Statistics 
To evaluate dependence of mean BMU velocity, mean osteonal area, and total crack 
length per unit area of bone cross-section on bisphosphonate treatment, a one-way ANOVA 
utilizing a Tukey posthoc comparison was performed using Minitab (Minitab Inc.; State College, 
PA). P-values less than 0.05 were considered statistically significant and represented significant 
difference between the treatment groups. The ANOVA was verified by performing a test for 
equality of variance and normality for each data set. Equality of variance testing utilizing 
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Levene's test statistic showed significance of equality for p > 0.05. Normality testing analyzed 
the data set's residuals using the Anderson-Darling method which showed normality for p > 
0.05. 
T-test analysis was performed for the equilibrium crack surface density values to look for 
equality between the equilibrium values and the measured values where the null hypothesis was 
that the equilibrium crack surface density was equal to the measured crack surface density. 
Similar analysis was also performed for the measured On.Ar values for the CON, ALNO.2 and 
ALN1.0 treatments to see if the mean measured area was similar to the calculated effective 
osteonal resorption area. For each test, the null hypothesis was rejected for p < 0.05. 
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3. Results 
Effective Osteonal Area 
Using the equation developed by Martin [2]: 
Cr.Le = iCr.Le - (On.Ar x iCr.Le)Rs.Ar (1) 
where Cr.Le equals mean crack length, iCr.Le equals mean initial crack length, On.Ar equals 
mean osteonal area, and Rs.Ar equals mean resorption space density, data was taken from Allen 
et al [12] and analyzed. See Table 1 for three year values of crack length and resorption space 
density organized by treatment category. Twelve samples for each of the three treatment 
categories - control, 0.2 mg/kg Alendronate, and 1.0 mg/kg Alendronate (CON, ALNO.2, and 
ALNl.O respectively) - were measured by Allen et al. [12] to provide the data in Table 1. 
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Table 1: 3 year data by treatment for crack length and resorption space density. 
3 year 
Sample # Treatment Cr.Le Rs.Ar 
(mm) (mm2) 
59210 CON 0.04487 0.77256 
59211 ALN1.0 0.09284 0.67596 
59219 ALNO.2 0.07609 0.40838 
59230 ALNO.2 0.06811 0.71990 
59231 ALN1.0 0.09103 0.47557 
59234 CON 0.12996 
59235 ALNO.2 0.06926 0.61030 
59236 ALN1.0 0.06561 0.77620 
59238 ALN1.0 0.06971 0.67416 
59239 ALNO.2 0.06490 0.65326 
59244 ALN1.0 0.05488 0.59295 
59256 ALNO.2 0.06485 0.61265 
59257 CON 0.05847 0.55057 
59258 ALNO.2 0.07192 0.88063 
59315 CON 0.06880 1.28135 
59536 ALN1.0 0.06955 1.02281 
59677 CON 0.04754 0.82046 
60592 ALNO.2 0.06769 0.38463 
60593 ALN1.0 0.07078 0.69665 
60628 CON 0.06950 0.15427 
60629 ALNO.2 0.07447 0.57732 
60630 CON 0.68077 
60631 ALNO.2 0.08154 0.65338 
60632 CON 0.06957 0.29406 
60634 CON 0.07113 0.13583 
60636 ALNO.2 0.06506 0.15357 
60641 ALN1.0 0.07902 0.12191 
60642 ALNO.2 0.08264 0.22093 
60643 ALN1.0 0.07534 0.46634 
60644 CON 0.04548 0.74438 
60645 ALNO.2 0.08629 0.14696 
60657 ALN1.0 0.08190 0.63245 
60667 CON 0.06471 0.73417 
60707 CON 0.04920 0.00000 
60750 ALN1.0 0.05774 0.25834 
60809 ALN1.0 0.07237 0.25422 
Using the data in Table 1 and Martin's equation, crack length (Cr.Le) was graphed with respect 
to resorption space density (Rs.Ar) for each treatment category as seen in Figures 16 - 18. 
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Figure 17. Crack length graphed with respect to resorption space density for control (CON) treatment. Effective 
osteona1 resorption area is calculated by dividing the magnitude of the slope by the y-intercept. 
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Figure 18. Crack length graphed with respect to resorption space density for Alendronate 0.2 mg/kg (ALNO.2) 
treatment. Effective osteonal resorption area is calculated by dividing the magnitude of the slope by the y-intercept. 
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Figure 19. Crack length graphed with respect to resorption space density for Alendronate 1.0 mg/kg (ALNl.O) 
treatment. Effective osteonal resorption area is calculated by dividing the magnitude of the slope by the y-intercept. 
Martin's equation assumes that the data follows a linear relationship, the slope of the line of best 
fit through the data represents the product of osteonal area and initial crack length, and the y-
intercept of the line of best fit represents the initial crack length. By dividing the slope of the line 
of best fit by y-intercept and converting units to 11m in Figures 1 - 3, the effective osteonal area is 
obtained. The effective osteonal area is then compared to the measured osteonal area for each 
sample as displayed in Table 2. 
Table 2: Effective osteonal resorption area and actual osteonal area by treatment 
3 year 
Treatment Effective Measured 
On.Ar (IJm 2) On.Ar (IJm2) 
CON 1.783x105 1.392x104 
ALNO.2 1.441 x105 1.135x104 
ALN1.0 2.022x104 1.542x1Q4 
The three year data shows an effective osteonal area of 1.783x 105, 1.441 x105, and 2.022x 104 
11m2 for the CON, ALNO.2, and ALN1.0 treatments respectively. Measured osteonal areas for the 
three year samples are 1.392x 104, 1.135x 104, and 1.542x 104 11m2 for the CON, ALNO.2, and 
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ALN 1.0 treatments respectively. These effective areas correspond to osteonal diameters of 
476.46,428.34, and 160.45 /lm for the CON, ALNO.2, and ALNl.O treatments respectively 
while the measured osteonal areas cOiTespond to osteonal diameters of 133.14, 120.23, and 
140.11 /lm with respect to the CON, ALNO.2, and ALNl.O treatments. The three year data shows 
an effective osteonal area approximately 12.8 times as large as the measured osteonal area for the 
CON group and an effective osteonal area approximately 12.7 times as large as the measured 
osteonal area for the ALNO.2 treatment. The effective osteonal area is nearly similar to the 
measured osteonal area for the ALN 1.0 treatment. The effective osteonal areas for the CON and 
ALNO.2 treatments are an order of magnitude larger than the effective osteonal area for the 
ALN 1.0 treatment. 
BMU Velocity 
BMU velocity calculations were made for the three year samples by measuring the 
distance between double-labeled BMUs in longitudinal sections following the method of 
Jaworski and Lok [17] and then dividing the length measurements by 12 - the number of days 
between labeling injections. Velocity data for the three different treatments (CON, ALNO.2, and 
ALNl.O) can be seen in Table 3. 
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Table 3: BMU velocity, measured osteonal area, and crack surface density by treatment. 
Sample
Number
59210
59211
59219
59230
59231
59234
59235
59236
59238
59239
59244
59256
59257
59258
59315
59536
59677
60592
60593
60628
60629
60630
60631
60632
60634
60636
60641
60642
60643
60644
60645
60657
60667
60707
60750
60809
Treatment 
Group 
CON 
ALN1.0 
ALNO.2 
ALNO.2 
ALN1.0 
CON 
ALNO.2 
ALN1.0 
ALN1.0 
AL1'J0.2 
ALN1.0 
ALNO.2 
CON 
ALNO.2 
CON 
ALN1.0 
CON 
·ALNO.2 
ALN1.0 
COI'J 
ALNO.2 
CON 
ALNO.2 
CON 
COI'J 
ALNO.2 
ALN1.0 
ALNO.2 
ALN1.0 
COI'J 
ALNO.2 
ALN1.0 
CON 
CON 
ALN1.0 
ALN1.0 
V.BMU 
(IJm/day) 
21.8000 
23.1500 
16.6400 
14.1000 
4.9700 
26.8500 
20.6200 
7.3400 
14.8500 
23.9500 
11.9800 
34.5400 
8.4500 
12.7400 
4.3900 
10.0900 
8.3600 
5.4700 
24.4100 
10.8700 
26.4500 
15.9900 
12.1100 
21.9700 
6.1200 
7.8800 
18.0700 
4.8300 
12.4600 
14.8000 
11.3500 
18.6000 
7.4000 
21.9100 
18.4600 
Measured 
On.Ar (~m2)
12671.280 
12529.640 
9261.140 
17875.933 
6723.558 
9918.595 
11499.070 
17174.090 
9570.580 
19004.800 
12011.710 
13245.650 
15310.070 
25273.850 
10365.970 
15748.200 
10553.058 
er.S.On 
(IJm/mm 2) 
10.074 
15.485 
84.403 
14.251 
67.963 
37.743 
29.717 
32.326 
34.229 
7.933 
19.804 
26.958 
41.581 
38.130 
50.578 
9.740 
74.703 
62.150 
83.539 
23.732 
91.402 
5.515 
66.902 
10.352 
80.388 
48.916 
34.993 
15.682 
57.832 
48.304 
4.614 
11.845 
28.786 
30.544 
Average BMU velocity is 19.12, 14.16, and 11.33 I-un/day for the CON, ALNO.2, and ALN1.0 
treatments respectively (Table 4). 
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Damage Formation 
Table 3 also contains measured osteonal area (On.Ar) and crack length per unit area of 
bone cross-section (CLS.Dn) data. Osteonal area and crack density measurements are provided 
by Matt Allen et al. BMU velocity, osteonal area and crack density are related to BMU damage 
removal by the following equation: 
[d(Cr.S.Dn)/dt]removal = V.BMU x On.Ar x Cr.S.Dn. (2) 
Using the values from Table 3, the rate of damage removal for the control specimens is found to 
be 6605.66 Ilm2/day. Making the assumption that in a steady state situation damage removal is 
equal to damage fonnation, damage formation is also equal to 6605.66 Ilm2/day. Under 
treatment, with changing values ofY.BMU and On.Ar, a new equilibrium crack surface density 
will be reached that is represented by the following equation: 
E _ [d(Cr.SDn)/ dt]/ormo,ion
Cr.S.Dn - T T' (3)
V,SMU x On.Ar 
Average values for the V.BMU, On.Ar, and Cr.S.Dn data present in Table 3 are shown below in 
Table 4. 
Table 4: Average BMU velocity, average measured osteonal area, and average crack surface
density by treatment.
Treatment Ave. V.BMU Ave. Measured Ave. er.S.On
Group (lJm/day) On.Ar (~m2) (lJmtmm 2)
CON 19.118 13922 24.818 
ALNO.2 14.163 11352 44.912 
ALN1.0 11.327 15418 40.764 
Using equation 3 and the damage fonnation rate determined for the control group, an equilibrium 
crack surface density was calculated for both the ALNO.2 and ALNI.O groups. For the ALNO.2 
and ALNO.1 treatments, the equilibrium crack surface density is 41.086 and 37.822 Ilm/mm2 
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respectively. Measured Cr.S.Dn values are 44.912 and 40.764 flmlmm2 for the ALNO.2 and 
ALN1.0 treatments respectively as seen in Table 4. 
Statistics 
An ANOVA was performed to explore the relationship between actual osteonal area, 
BMU velocity, and crack surface density with respect to the three treatment groups. Results are 
found in Table 5 for the ANOVA using a Tukey posthoc comparison. 
Table 5: ANOVA results for BMU velocity, measured osteonal area, and crack surface density 
by treatment 
CON ALNO.2 ALN1.0 p 
V.BMU (J-Im/day) 19.18±8.25 14.16 ± 5.3 11.33±7.13* 0.036 
Measured On.Ar 
(J-Im2 ) 13922 ± 2940 11352 ± 4185 15418 ± 6134 0.338 
Measured Cr.SDn 
(J-Im/mm 2 ) 24.82 ± 27.38 44.91 ± 27.27 40.76 ± 21.56 0.157 
Data are mean ± SD. P values refer to a one-way ANOVA among the three groups: * vs. CON 
Individual p values for each Tukey comparison for measured On.Ar and Cr.S.Dn were all greater 
than 0.05 which is reflected in the overall p value reported in Table 5. The p values for the 
individual Tukey comparisons performed for BMU velocity are presented in Table 6. 
Table 6: P values for individual Tukey comparisons for BMU velocity one-way ANOVA 
Comparisons P 
CON and ALNO.2 .0922 
CON and ALN1.0 .0119 
ALNO.2 and ALN1.0 .3387 
The ANOVA was verified by checking for equality of variance and normality for each data set. 
Equality of variance testing utilizing Levene's test statistic showed significance of equality for p 
> 0.05. Normality testing analyzed the data set's residuals using the Anderson-Darling method 
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which showed normality for p > 0.05. See Figures 19,20, and 21 for graphical representation of 
the tests for equality of variance and normality. 
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Figure 20. Test for equality of variance and normality for Y.BMU ANOYA. 
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Figure 21. Test for equality of variance and normality for measured On.Ar ANOYA. 
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Figure 22. Test for equality of variance and normality for Cr.S.Dn ANOYA. 
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The normality test for Cr.S.Dn has p < 0.05 which would usually signify a failure of normality 
but the deviations from normality, in this case, won't interfere with the conclusions drawn from 
the ANOVA of the Cr.S.Dn data. A clustering of data points in the Cr.S.Dn data set is causing 
the failure, but this clustering can be overlooked as inconsequential due to the nature of the data 
thus the ANOVA is valid [19] 
T-test analysis was performed for the equilibrium crack surface density values to look for 
equality between the equilibrium values and the measured values. Similar analysis was also 
performed for the measured On.Ar values for the CON, ALNO.2, and ALNI.O treatments to see 
if the mean measured area was similar to the calculated effective osteonal resorption area. 
Beginning with the ALNl.O treatment area calculations, it was found through a one-sample t-test 
analyzing the measured On.Ar data, that the mean of the On.Ar data was similar to the calculated 
effective area with p = 0.155. The null hypothesis, that the mean of the On.Ar data was the same 
as the calculated effective area, was not rejected because p > 0.05 and the effective osteonal area 
is statistically similar to the measured osteonal area for the ALNI.O treatment. T-tests for the 
CON and ALNO.2 groups showed that there was a significant difference between the effective 
osteonal area and the measured actual osteonal area. P values for these t-tests were both less than 
0.001 resulting in a rejection of the null hypothesis. With respect to equilibrium crack surface 
density, the null hypothesis being tested was that the mean measured crack surface density was 
the same as the calculated equilibrium crack surface density for the ALNO.2 and ALNl.O groups. 
T-test results yield p values greater than 0.05 for both the ALNO.2 and ALNI.O groups. Thus it 
can be assumed that the equilibrium crack surface density values are equal to the mean measured 
crack surface density for both the ALNO.2 and ALNI.O treatments. 
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4. Discussion 
The objective of this study was to investigate the relationship between long-term 
bisphosphonate use (3 years), microdamage targeting by BMUs, BMU velocity, and crack 
density in canine rib bones. The canine model was selected for this study because the remodeling 
dynamics appear to be similar between human and canine cortical bone [17]. Bisphosphonate 
doses used in this research were administered on a milligram per kilogram of body weight basis 
in order to parallel common dosage levels used to treat postmenopausal osteoporosis in the 
clinical setting. Canines are also suitable for studies involving bone remodeling dynamics 
because they show evidence of osteocyte apoptosis and microcrack accumulation. The 
hypotheses under investigation are as follows: 1) BMUs are drawn toward microdamage in the 
bone matrix and effectively steer towards microcracks as they tunnel through bone along the 
dominant lines of force present in bone, 2) Bisphosphonates will have the effect of decreasing 
the calculated effective resorption area ofBMUs, and thus decrease their ability to steer, in a 
dose dependent manner, and 3) Bisphosphonates will reduce the tunneling velocity and actual 
osteonal area ofBMUs thus effecting a new equilibrium crack surface density, under the 
assumption of steady stage damage formation and removal. Data comes from samples supplied 
by Allen et al. [12] from the Indiana University School of Medicine. This study is unique in that 
it combines the canine rib model with bisphosphonate treatment spanning a three year time 
period. Previous long-term studies focused on vertebral remodeling or lasted one year [13, 14, 
20,21,22,23]. 
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Microdamage Targeting 
The three year study data supports the hypothesis that BMUs target microdamage and are 
steered by microcracks in the bone matrix. For two of the treatments (CON and ALNO.2) the 
calculated effective osteonal area is greater than the measured osteonal area. Following Martin's 
study [2], the results support his assertion that BMUs are drawn towards microcracks as they 
tunnel through bone following the dominant lines of force. In the case of the control group, the 
effective osteonal area is approximately 12.8 times as large as the measured osteonal area. At 
1.39xl04 11m2, the measured osteonal area is 7.8% of the 1.78x10511m2 value derived from 
Martin's equations. The effective osteonal area corresponds to an effective osteonal diameter of 
476 11m, which is significantly larger than the 120 ± 28 Jlm range predicted by Jaworski and Lok 
[17] for BMUs in canine cortical bone and the 150 to 220 Jlm range predicted by Moyle and 
Bowden [11] for BMUs in human cortical bone. The ALNO.2 treatment group also shows an 
increased effective osteonal area compared to the measured value. The lower dose Alendronate 
treatment (ALNO.2) exhibits an effective osteonal area of I.44xl051lm while the measured 
osteonal area is I.I4x104/lm, and the higher dose Alendronate treatment (ALN1.0) exhibits an 
effective osteonal area of2.02x1041lm while the measured osteonal area is 1.54x104 11m. For the 
ALNO.2 treatment, the measured osteonal area is 8% of the effective area value and yields an 
effective osteonal area that is greater than the measured osteonal area. Statistical analysis shows 
that the calculated effective osteonal area is significantly similar to the measured osteonal area 
for the ALN 1.0 treatment indicating that microdamage targeting does not occur for the high dose 
Alendronate treatment. Only the CON and ALNO.2 treatment groups support the hypothesis that 
BMUs target and steer towards microdamage as they tunnel through bone during the remodeling 
process. These findings also support the assertions made by Burr that about 30% of bone 
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remodeling is targeted to the repair of microdamage [24]. The larger-than-measured effective 
osteonal areas demonstrate that BMUs are straying from their trajectories along the principle 
loading directions in bone to seek out microdamage. Although Burr's hypothesis regarding 
targeted repair of microdamage has yet to be experimentally or computationally proven, the 
present data lends support to the idea that remodeling targets microdamage. 
The second hypothesis is addressed by observing the relationship between the effective 
osteonal area and bisphosphonate dosage. The presence of bisphosphonates seems to have a 
suppressive effect on the effective osteonal area. Li et al. [20] found that bisphosphonate 
treatment suppressed both targeted and nontargeted (stochastic) remodeling along with targeted 
repair of microdamage. Li's study administered both Risedronate and Alendronate 
bisphosphonates to skeletally mature beagles and assessed the association between cracks and 
resorption spaces. The study observed that there were fewer cracks associated with resorption 
spaces than expected in the Risedronate and Alendronate groups indicating that both targeted and 
non-targeted remodeling are suppressed. Their findings are supported by current results in that 
the calculated effective osteonal area of the ALN1.0 group is observed to decrease from that of 
the control group's. As stated above, the effective osteonal area of the CON group was 12.8 
times larger than the measured area while the effective osteonal area of the ALN 1.0 group was 
statistically similar to the measured area. In addition, the effective osteonal area for the CON 
group was a factor of 10 larger than that for the ALNl.0 treatment group. Bisphosphonate 
treatment at the high dose level caused a decrease in the ratio of effective osteonal area to actual 
osteonal area with respect to the CON and ALN 1.0 groups. The difference in the ratio of 
effective osteonal area to actual osteonal area with respect to the CON and ALNO.2 groups was 
less decisive. The effective osteonal area calculated for the ALNO.2 group was 12.7 times as 
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large as the actual osteonal area while the effective area for the CON group was 12.8 times as 
large as the actual osteonal are. Statistical analysis shows that for both the CON and ALNO.2 
groups, the calculated effective area is significantly different that the measured osteonal area. 
The ALNO.2 treatment seems to have little suppressive effect on the effected area while the 
ALNI.O seems to have a large suppressive effect on the effective area. This observation was 
most likely the result of the dosage level of the bisphosphonate treatment. The data seems to 
indicate that suppression of the effective osteonal area doesn't occur at the lower bisphosphonate 
dose level but requires a dose approximately five times higher than clinical osteoporosis 
treatment levels to achieve the suppressive effect. This suppressive action is expected since the 
action ofbisphosphonates is to inhibit BMU activation and the ability of osteoclasts to absorb 
bone. If the ability of osteoclasts to tunnel through bone is inhibited, then they won't be as able 
to steer towards microdamage. Suppressing BMUs in such a way decreases their effectiveness 
during remodeling and explains the decrease in effective resorption area seen in this study. These 
results support the hypothesis that bisphosphonates suppress the microdamage targeting ability 
of BMUs in a dose dependent marmer. As mentioned above, one-sample t-test statistical analysis 
comparing the effective osteonal area to the measured osteonal area determined that the effective 
area for both the CON and ALNO.2 differ from the measured, actual osteonal area. The null 
hypothesis for the one-sample t-test is that the mean measured osteonal area is equal to the 
effective osteonal area. P values for the analysis involving the CON and ALNO.2 treatments were 
below 0.05 resulting in the rejection of the null hypothesis. T-test results for the ALNl.O 
treatment led to the conclusion that the effective and measured areas do not different from each 
other. These results support the second hypothesis of this study and show that the effective 
osteonal resorption area is diminished with increased dose ofbisphosphonate treatment. In 
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regards to BMU targeting of microdamage, it is implied that a decreased effective osteonal 
resorption area results in decreased ability to steer towards microdamage. The data showing that 
the effective area of the ALN 1.0 treatment doesn't differ from the measured area further 
illustrates the decreased ability of BMUs to steer towards microdamage while under 
bisphosphonate treatment. Ifbisphosphonates didn't have an effect on BMU steering, it is 
expected that the effective osteonal area would match the CON group value in experimentation 
involving any dose of bisphosphonate treatment. 
Actual Osteonal Area 
Contrary to this observation of suppressed effective osteonal area, the measured osteonal 
area is similar between all three experimental groups. Even though targeted remodeling is being 
suppressed by bisphosphonate treatment, the actual resorption area of active osteons remains at 
normal values. Statistical analysis reveals that the mean measured osteonal areas are statistically 
similar for the CON, ALNO.2, and ALNl.O treatments. While it was hypothesized that actual 
osteonal area would decrease with bisphosphonate use this is clearly not the case. The hypothesis 
was formed based on research examining the suppressive affects ofbisphosphonates on the 
remodeling process. It was thought that inhibited BMUs would be unable to form osteons of 
normal size due to the inability of osteoclasts to properly resorb bone. Osteoclasts would be less 
effective at creating normal sized resorption cavities which would result in osteons with lower 
than normal areas after bone formation by osteoblasts. The analysis perforrn.ed in this study 
refutes the hypothesis that bisphosphonate treatment reduces actual osteonal area in a dose 
dependent manner since the measured osteonal areas were shown to be statistically significant 
among all three treatment groups. 
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BMU Velocity 
In a three year study by Allen et al. the toughness ofbone was analyzed in relation to 
bisphosphonate treatment and microdamage accumulation. Under Alendronate treatment, bone 
toughness decreased without an overall accumulation of microdamage [12]. Bisphosphonate 
doses mirrored doses given in the present study, and significant losses in toughness were noted 
only for the ALNl.0 treatment group [12]. This result seems to parallel the decrease in the 
effective osteonal area calculated in the present study in that only the higher dose of 
bisphosphonate treatment has an effect on the scrutinized property. Across all three treatment 
groups in Allen's study (CON, ALNO.2, and ALNI.O) there was no significant difference in 
overall microdamage accumulation. Taking Allen's work a step further, the effect of 
bisphosphonate treatment on BMU velocity was explored in the study presented here. Average 
velocities for the 12 samples in the CON, ALNO.2, and ALNl.O treatments were 19.12, 14.16, 
and 11.33 !-un/day respectively. Analysis revealed no significant difference in the average 
velocity for the CON and ALNO.2 treatments. Conversely, a significant difference in the average 
velocities of the CON and ALNl.O groups was noted. Analysis comparing BMU velocity for the 
ALNO.2 and ALNl.0 groups reveals that they are statistically similar. It can be reasoned that 
high dose bisphosphonate treatment decreases BMU velocity by observing the significant 
difference between the CON and the ALNl.O treatment groups. The lack of significance in 
velocity differences between the CON and ALNO.2 treatments may be due to a threshold effect 
with respect to bisphosphonate dose level. There may be a critical dosage level that once 
surpassed causes a significant decrease in BMU velocity from the control like that seen for the 
ALNl.0 treatment. The significance of the decrease in average velocity between the CON and 
ALNl.O treatments shows a suppressive effect ofbisphosphonate treatment at high dose levels. 
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Crack Surface Density 
As part of the analysis of Allen et al. on the effects of bisphosphonates on bone toughness 
and microdamage accumulation [12], mean crack length, crack number, and crack surface 
density were calculated. Utilizing mean crack length, crack number, and crack surface density, 
Allen et al. [12] concluded that there were no significant differences in overall microdamage 
accumulation between the CON, ALNO.2, and ALNl.0 treatments although mean crack length 
was higher in both the ALNO.2 and ALNl.O groups compared to the CON group [12]. The 
present study furthers the analysis of Allen et al. [12] by validating a model to predict 
equilibrium crack surface density values in an assumed steady state condition with respect to 
damage formation and removal. The third hypothesis is evaluated using the average values of 
BMU velocity, actual osteonal area, and crack surface density for the CON group to calculate the 
steady state value of damage formation and removal following the equations: 
[d(Cr.S.Dn)/dt]removal = Y.BMU x On.Ar x Cr.S.Dn (1) 
E [d(Cr.S.Dn) / dt] formation 
Cr.S.Dn = T T' (2)
V.BMU X On.Ar 
In equations (1) and (2), Y.BMU equals BMU velocity, On.Ar equals measured osteonal area, 
Cr.S.Dn equals crack length per unit area of bone cross-section, Cr.S.DnE equals equilibrium 
crack surface density, V.BMUT equals the BMU velocity under treatment, On.ArT equals the 
osteonal area under treatment, and [d(Cr.S.Dn)/dt]removal and [d(Cr.S.Dn)/dt]formation equal damage 
removal and formation respectively. At steady state with respect to the remodeling process, it is 
assumed that due to normal BMU activity, the amount of damage formed in the bone matrix is 
equal to the amount of damage removal by the remodeling process. Using the steady state 
damage formation value and dividing by the treatment values of BMU velocity and actual 
osteonal area an equilibrium crack surface density was calculated for both the ALNO.2 and 
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ALN1.0 treatments. Equilibrium crack surface density values were 41.086 and 37.822 Ilm/mm2 
for the ALNO.2 and ALN1.0 treatments respectively. The measured values of crack density were 
44.912 and 40.764 Ilm/mm2 for the ALNO.2 and ALN1.0 treatments respectively. Statistical 
analysis comparing the calculated equilibrium values to their corresponding measured values 
showed no significant difference in the values. This conclusion supports the third hypothesis by 
validating the steady state crack density model. The equilibrium crack surface density values are 
equal to the measured crack surface density values as predicted, thus verifying equation (2). As 
Y.BMU decreases, On.AT and [d(Cr.S.Dn)/dt]formation remain the same under treatment and the 
equilibrium crack surface density should increase above the control value. Statistical analysis 
determined that there is no significant difference in measured mean crack surface density 
between the control and Alendronate treatments. Current crack surface density data fails the 
Anderson-Darling normality test (p < 0.05), but the deviations from nOimality, in this case, 
won't interfere with these conclusions because of the insignificant clustering effect of the data 
[19]. It follows logically that as bisphosphonate treatment inhibits the remodeling process, the 
crack surface density will increase as damage accumulates until a new equilibrium is reached 
between damage formation and damage removal. This conclusion is supported by research 
performed by Allen and colleagues in a study where crack surface density was seen to increase 
over control values with the administration ofbisphosphonates for a one year time frame [14]. 
Allen's one year study [14] analyzing the microdamage accumulation in canine vertebral bone 
found that crack surface density increased across all the Alendronate doses (ALNO.l, ALNO.2, 
ALN1.0) compared to the control group. The doses of bisphosphonates used in the study 
correspond to clinical treatment levels for postmenopausal osteoporosis, half that value, and five 
times that value (used to treat Paget's disease). Allen also noted that although bisphosphonate 
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treatment allowed significant microdamage accumulation in the vertebra, the detrimental effects 
were offset by increases in bone volume and mineralization such that there was no significant 
impairment of mechanical properties [14]. A later study by Allen and Burr examined the damage 
accumulation effects of bisphosphonates on canine vertebra over a three year period and 
compared the data to one year findings [13]. They concluded that while three years of 
Alendronate treatment resulted in higher vertebral microcrack density (#/mm2) than for one year 
of treatment, the amount of microdamage accumulation (determined by crack surface density, 
l.unlmm2) was not significantly different than the one year Alendronate treatment [13]. Allen and 
Burr reasoned that damage accumulation due to bisphosphonate use occurs early in treatment so 
there is little further damage seen after this period. Crack surface density in vertebral bone 
reported by Allen and Burr was not significantly different among the treatment groups. The 
current study's results seem to parallel Allen and Burr's findings as the steady state model 
predicts that equilibrium crack surface density is similar to measured values for both the ALNO.2 
and ALN1.0 treatments over a three year period. Present data also supports and confirms Allen 
and Burr's results that there was no significant difference in crack surface density among 
treatment groups as seen from the results of the previously mentioned one-way ANOVA 
showing that there is no significant difference comparing measured crack surface density 
between the CON, ALNO.2, and ALNl.O treatment groups. 
Conclusions 
This experimental study examined the theory of microdamage targeting by BMUs and 
evaluated the effects of bisphosphonate treatment on remodeling dynamics. The results and 
analysis aid in the understanding of the effective osteonal resorption area that is a result ofBMU 
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steering. Data analysis also shows the dose dependent nature of bisphosphonates on remodeling 
dynamics. The main conclusions to be drawn from this study are reported below: 
1. Current research has shown that BMU steering is a highly plausible 
explanation for targeted remodeling. Work done by Martin [2], conceming the 
calculation of an effective osteonal resorption area that is greater than the 
measured osteonal resorption area, is supported by this experimental study. 
2. Bisphosphonates are seen in multiple studies to decrease the occurrence of 
bone remodeling thus allowing the accumulation of microdamage [12, 13, 14, 
20,22,23]. While suppressing the remodeling process, bisphosphonates also 
suppress the ability of BMUs to steer towards microdamage as seen in the 
dose dependent decrease of effective osteonal resorption area. 
3. Bisphosphonates also have a suppressive nature in regard to remodeling 
dynamics and decrease BMU tunneling velocity while leaving the actual 
osteonal area unaffected. 
4. An extrapolation of Martin's model describing the effective resorption area of 
BMUs successfully shows that the new steady state equilibrium condition in 
damage removal and formation achieved under bisphosphonate treatment is a 
valid predictor of crack surface density. 
5. Mean crack surface density for all three treatment groups (CON, ALNO.2, and 
ALN1.0) is not significantly different which supports results in previous 
studies examining the effects of bisphosphonate treatment on the remodeling 
process [12, 13]. 
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Recommendations for Future Work 
Currently, postmenopausal osteoporosis is a major disease affecting a majority of older 
women. While predominantly diagnosed in women, osteoporosis also affects older men. The 
main treatment for this disease is bisphosphonate medication meant to depress the remodeling 
process in order to halt bone loss. To date, the effects of long term bisphosphonate treatment in 
humans are not fully understood and complications involving microdamage accumulation may 
exist that outweigh the risk of fracture encountered when not taking bisphosphonate drugs. More 
long term studies concerning fracture risk associated with bisphosphonates are needed to better 
quantify the benefits of bone remodeling suppressing drugs. 
There are many present theories that offer explanations for the activation and movement 
ofBMUs as they tunnel through bone. The model explored in this study focuses on BMU 
steering by microcracks present in the bone matrix. Further studies that explore the effective 
resorption area demonstrated by Martin [2] can be used to add support or refute his theory. After 
observing the effects of microcracks on the effective resorption area of BMUs it would be 
beneficial to correlate osteocyte apoptosis or osteocyte signaling to explore their relationship to 
BMU steering. 
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